No information is available on the clinical use of bosutinib during breastfeeding. Because bosutinib is 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 22 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during bosutinib therapy and the manufacturer recommends withholding breastfeeding until 2 weeks following the last dose.[1]
关于波舒替尼在母乳喂养期间的临床应用尚无可用信息。由于波舒替尼与血浆蛋白的结合率为96%，乳汁中的含量可能较低。然而，其半衰期约为22小时，可能会在婴儿体内蓄积。美国国立综合癌症网络指南建议在波舒替尼治疗期间避免母乳喂养，制造商建议在最后一剂后2周内停止母乳喂养。[1]
